Invivyd receives HCPCS reimbursement codes from CMS covering PEMGARDA

Invivyd announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has granted a Healthcare Common Procedure Coding System, HCPCS, Q code covering product reimbursement for PEMGARDA. In addition, CMS issued a product specific M code covering the administration of PEMGARDA. Both HCPCS codes are effective retroactively to March 22, 2024, the date of emergency use authorization for PEMGARDA. “CMS provides coverage for nearly half of the moderately to severely immunocompromised people at highest risk for severe COVID-19 whom we are targeting, and obtaining a Q code that secures PEMGARDA reimbursement for such a significant population marks another key milestone in our efforts to bring this important molecule to those individuals,” said Jeremy Gowler, Interim Chief Executive Officer at Invivyd. “While still in the very early days of the launch, we have already seen exciting initial interest in PEMGARDA from patients and prescribers, sold and shipped product, and engaged in constructive conversations with a range of commercial payors. Momentum is building, and I look forward to providing additional updates on our commercial progress in the months ahead.”